Neuland Laboratories Limited (NEULANDLAB) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch
Neuland Laboratories enters its Q1 FY27 results following a record-breaking fiscal year that saw the company scale its Custom Manufacturing Solutions (CMS) pipeline to 98 active projects. Investors will be focused on whether the company can maintain its operating momentum as it transitions from a record Q4 FY26 performance toward its long-term growth targets.
| Results date | August 05, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Previous quarter revenue | Rs. 788.7 Cr |
| Previous quarter PAT | Rs. 212.5 Cr |
| Previous quarter EBITDA margin | 40.5% |
| Net debt (latest quarter) | Rs. (157) Cr |
| Market cap | Rs. 24,253.69 Cr |
| CMP | Rs. 18,904.05 |
Neuland Laboratories Limited Q1 Results Date and Time
The company has scheduled a board meeting for August 5, 2026, to approve the unaudited Q1 FY27 financial results.
The earnings conference call is scheduled for August 5, 2026, at 17:30 Hrs IST.
What to expect from Neuland Laboratories Limited's Q1 FY27 results
Neuland Laboratories' Q1 FY27 performance is expected to show YoY growth against the Q1 FY26 base of Rs. 300.6 Cr, supported by a favorable USD/INR tailwind and a growing CMS order book. While Q4 FY26 revenue reached a record Rs. 788.7 Cr, management has characterized that quarter as inherently uneven, suggesting a potential moderation in sequential development revenue.
EBITDA margins are expected to normalize toward the company's guided sustainable band of 25-30% after the exceptional 40.5% margin recorded in Q4 FY26. Ongoing geopolitical tensions in the Red Sea continue to pose a freight cost headwind, while the company remains focused on its capital-intensive expansion, including the Unit 1 capacity addition of 120.5 KL and the commissioning of the Peptide Module-1 facility in FY27.
Key Things To Watch
Performance vs Guidance Tracking: Monitoring progress against long-term aspirational targets and recent project milestones.
- Revenue CAGR — 18-20% aspirational target — Reaffirmed in Q4 FY26
- EBITDA margin — 25-30% sustainable range — FY26 actual at 29.4%
- Peptide Module-1 — Ready and operational in FY27 — On track as of Q4 FY26
Strategic Capex and Capacity Expansion: Tracking the execution of major infrastructure investments to support future growth.
- Unit 1 expansion — Investment of Rs. 143.4 Cr for 120.5 KL capacity — 12-18 month timeline from May 2026
- Peptide production suite — Investment of Rs. 1,000 Cr plus — Open-ended timeline
- Genome Valley R&D Centre — 140k Sq Feet leased facility — Board approved
Operating Metric Trajectory: Assessing the sustainability of CMS project conversion and revenue quality.
- Active CMS projects — 98 total as of Q4 FY26 — Growth from 97 in Q4 FY25
- CMS Development revenue — Rs. 488 Cr in Q4 FY26 — Assessment of run-rate sustainability
- Working capital — 137 days of sales in Q4 FY26 — Improvement from 145 days in Q3 FY26
Risks and Headwinds to Monitor: Evaluating external factors impacting margin and supply chain stability.
- Freight costs — Elevated due to Red Sea conflict — Ongoing monitoring for margin impact
- Revenue lumpiness — Inherently uneven shipments — Management guidance remains conservative
- Raw material volatility — Budgeted conservatively — Potential impact on quarterly realizations
Ask about this
Ask Cofacto a question about this company. Answers cite filings and company data.
Frequently Asked Questions
What is the status of Neuland Laboratories' peptide manufacturing capacity?
The company's Peptide Module-1 facility is expected to be ready and operational in FY27. Management is also planning a full large-scale peptide production suite with an estimated investment of over Rs. 1,000 crore.
How does the company manage its EBITDA margin volatility?
Management notes that margins are influenced by exchange rates and product mix, leading to inherent quarterly lumpiness. While the company guides for a sustainable 25% to 30% EBITDA margin, they tend to be conservative in their budgeting, which often results in margins performing better than initial projections.
Is Neuland Laboratories' revenue growth sustainable?
Management considers growth for the next 2 to 3 years to be preordained by existing products, requiring execution discipline. The company's revenue growth is supported by a robust pipeline of commercial and near-commercial molecules, with 98 active CMS projects as of Q4 FY26.